Envoy Medical, INC 8-K filings

Envoy Medical, Inc. reports the departure of Chief Financial Officer David R. Wells, effective May 16, 2025, with CEO Brent T. Lucas stepping in as interim principal financial officer.

Envoy Medical announces its Q1 2025 financial results and provides an update on its pivotal clinical study for the fully implanted Acclaim cochlear implant, including securing additional funding and completing enrollment of the first stage of the trial.

Envoy Medical announces its Annual Meeting of Stockholders will be held on May 28, 2025, and sets deadlines for director nominations and stockholder proposals.

Envoy Medical announces its Q4 and full year 2024 financial results, along with a corporate update emphasizing progress in the pivotal clinical study for its Acclaim Cochlear Implant.

Envoy Medical obtains $10 million in financing from Glen Taylor to support the Acclaim cochlear implant pivotal clinical trial and other operations.

Envoy Medical, Inc. received a notification from Nasdaq on February 25, 2025, indicating non-compliance with listing rules due to its market value falling below the required minimum.

Envoy Medical, Inc. has entered into an agreement with Roth Capital Partners to sell up to $15 million of its Class A common stock through an at-the-market offering.

Envoy Medical has extended the expiration date of its shortfall warrants by 12 months to December 31, 2025, through an amendment with Meteora FPA Parties.

Envoy Medical and Anzu SPAC GP I LLC have entered into an agreement involving the conversion of preferred stock, a waiver of accrued dividends, and the removal of restrictions on certain common stock.

Envoy Medical has drawn the remaining $5 million from a promissory note with GAT Funding, bringing the total to $10 million, and issued warrants to purchase 500,000 shares as a commitment fee.

Envoy Medical's 2024 Annual Meeting saw the election of two directors, ratification of the accounting firm, and advisory votes on executive compensation.

Envoy Medical reports Q3 2024 financial results, highlights FDA approval for a pivotal cochlear implant trial, and secures key CPT codes for its middle ear implant.

Envoy Medical has announced its annual meeting of stockholders will be held on November 14, 2024, and has set deadlines for director nominations and stockholder proposals.

Envoy Medical has secured a $10 million lending facility from Glen Taylor, a major investor, to support the development of its fully implanted hearing devices.

Envoy Medical is advancing its fully implanted Acclaim cochlear implant, with positive early study results and plans to begin a pivotal clinical trial by the end of 2024, while reporting a slight increase in revenue for the second quarter.

A new bipartisan Senate bill aims to classify implanted active middle ear hearing devices as prosthetics, potentially making them eligible for Medicare coverage and benefiting companies like Envoy Medical.

Envoy Medical has amended its Forward Purchase Agreement with Meteora FPA Parties, lowering the exercise price floor for a portion of its outstanding warrants.

Envoy Medical, Inc. has drawn the final $2.5 million under a promissory note with GAT Funding, bringing the total to $10 million, and issued a warrant for 250,000 shares to GAT as a commitment fee.

Envoy Medical is advancing its fully implantable hearing device technology, including the FDA-approved Esteem and the investigational Acclaim cochlear implant, aiming to disrupt the hearing loss market.

Envoy Medical has extended the expiration date of its Shortfall Warrants by six months, from June 30, 2024, to December 31, 2024.

Envoy Medical has appointed Michael Crowe, a seasoned medical device executive, to its Board of Directors to support the company's growth and upcoming clinical trials.

Envoy Medical, Inc. has drawn an additional $2.5 million from GAT Funding, bringing the total owed under a promissory note to $7.5 million, and issued warrants to purchase 250,000 shares of its Class A Common Stock.

Envoy Medical announced its Q1 2024 financial results and provided updates on its fully implanted cochlear implant development, including a new $10 million loan facility.

Envoy Medical has secured up to $10 million in debt financing from Glen Taylor to support its upcoming clinical trial for the Acclaim cochlear implant.